Key result
DUTCH-AF registry evaluates the clinical impact of oral anticoagulation non-adherence in newly diagnosed AF.
Why the study?
Prospective registries with longitudinal data on anticoagulant therapy, treatment adherence, and adverse events in practice-based cohorts were lacking, particularly for NOACs.
What is the effect of non-adherence and non-persistence of anticoagulation therapy on clinical adverse events in patients with newly diagnosed non-valvular atrial fibrillation?
Population
Target of 6000 patients with newly diagnosed non-valvular AF across the Netherlands
Comparison
Adherence and persistence to anticoagulant therapy in routine clinical care
Design
Nationwide prospective registry programme and observational study
Follow-up
At least 2 years
Authors
Loading...
May inform real-world adherence risks in new AF; leaves open whether interventions improve persistence and outcomes.
Observational (n=6,000)
Yes
What is the effect of non-adherence and non-persistence of anticoagulation therapy on clinical adverse events in patients with newly diagnosed non-valvular atrial fibrillation?
The DUTCH-AF registry aims to provide longitudinal data on anticoagulant therapy adherence, persistence, and associated adverse events in a nationwide cohort of patients with newly diagnosed non-valvular atrial fibrillation.
Chu et al. (2020) conducted an observational in Atrial fibrillation (n=6,000). Oral anticoagulation therapy (adherence and persistence) vs. Non-adherence and non-persistence was evaluated on Thromboembolic and bleeding events, changes in antithrombotic therapy, and hospital admissions. The DUTCH-AF registry is a prospective nationwide observational study designed to evaluate the clinical impact of non-adherence and non-persistence to oral anticoagulation therapy in 6,000 patients with newly diagnosed atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: